~~18. A method of treating cancer comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition of any one of claims 1 to 17.~~

~~19. A method of claim 18, wherein the cancer is selected from the group consisting of ovarian cancer, non-small cell lung cancer, colon cancer, pancreatic cancer, skin cancer, oesophageal cancer, lung cancer and breast cancer.~~

~~20.~~ Use of a therapeutically effective amount of the pharmaceutical composition comprising trypsinogen and chymotrypsinogen, wherein the composition does not contain amylase, in the manufacture of a medicament for treating cancer, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1.

~~21.~~ Use of claim ~~20~~, wherein the pharmaceutical composition is of any one of claims 1 to 17.

~~22.~~ Use of claim ~~20~~ or ~~21~~, wherein the cancer is selected from the group consisting of ovarian cancer, non-small cell lung cancer, colon cancer, pancreatic cancer, skin cancer, oesophageal cancer, lung cancer and breast cancer.

°°

18. Use of a therapeutically effective amount of the pharmaceutical composition comprising trypsinogen and chymotrypsinogen, wherein the composition does not contain amylase, in the manufacture of a medicament for treating cancer, wherein the weight ratio of chymotrypsinogen:trypsinogen is in the range of between 4:1 to 8:1.

19. Use of claim 18, wherein the pharmaceutical composition is of any one of claims 1 to 17.

20. Use of claim 18 or 19, wherein the cancer is selected from the group consisting of ovarian cancer, non-small cell lung cancer, colon cancer, pancreatic cancer, skin cancer, oesophageal cancer, lung cancer and breast cancer.